Oxaprozin for arthritis
Article Abstract:
The US Food and Drug Administration has approved the drug oxaprozin (Daypro) for the treatment of osteoarthritis and rheumatoid arthritis. Like ibuprofen, oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID). Clinical trials found that 1,200 milligrams (mg) of oxaprozin taken once daily is at least as effective as aspirin in treating rheumatoid arthritis. Also, daily doses of 1,200 mg of oxaprozin appear to be as effective as ibuprofen doses of 1,200 to 1,800 mg in treating rheumatoid arthritis. A 1,200 mg dose of oxaprozin was as effective as 650 mg of aspirin in treating 105 patients with pain for the first four hours after oral surgery and was more effective than aspirin after four hours. Side effects associated with oxaprozin include abdominal pain, nausea and vomiting. As with other NSAIDS, some toxic effects may result from oxaprozin. Information on the effectiveness of oxaprozin is limited, and cheaper alternatives do exist.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1993
User Contributions:
Comment about this article or add new information about this topic:
New FDA Approvals
Article Abstract:
Celecoxib (Celebrex), a nonsteroidal anti-inflammatory drug (NSAID) used for treatment of osteoarthritis and adult rheumatoid arthritis, has been approved by the FDA. It is the first of NSAIDs that blocks the production of enzyme cyclooxygenase, preventing pain and inflammation. However, it does not block the production of enzyme Cox-1, which helps preserve the stomach lining.
Publication Name: The Nurse Practitioner
Subject: Health
ISSN: 0361-1817
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
New drugs for rheumatoid arthritis
Article Abstract:
The Food and Drug Administration approved leflunomide, etanercept, and infliximab for the treatment of rheumatoid arthritis. The drugs all block inflammatory processes that contribute to joint damage in the disease. It is not yet known if the drugs will slow the progression of rheumatoid arthritis, or merely relieve the symptoms.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: HLA typing in families with multiple cases of rheumatoid arthritis. Microheterogeneity of alpha-1 acid glycoprotein in rheumatoid arthritis: dependent on disease duration?
- Abstracts: Euro action on hepatitis B. Protection against hepatitis B. Hepatitis reports available
- Abstracts: Gazing into the future of reform. High stakes for health care
- Abstracts: Pet-borne illness. Pets and you: Companions for health. Activity therapy